S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL

por Heeney, M, Rees, D, de Montalembert, M, Odame, I, Brown, C, Wali, Y, Nguyen, T, Lam, D, Pfender, N, Kanter, J
Publicado 2022

Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anaemia

por Alkindi, S., Elsadek, R.A., Al-Madhani, A., Al-Musalhi, M., AlKindi, S.Y., Al-Khadouri, G., Al Rawahi, B., Al-Ruqeishi, S., Al-Yazeedi, J., Wali, Y.A., Al Shamakhi, S., Al Rawahi, M., Pathare, A.V.
Publicado 2021